mRNA therapeutics
Personalised mRNA cancer treatment has reported a positive result in a Phase 3 trial. Merck and Moderna say intismeran plus pembrolizumab reduced the risk of recurrence and of distant metastasis compared with pembrolizumab alone in resected melanoma. The treatment is not yet approved. Full results, overall-survival follow-up and regulatory review are still to come, and other cancers are unproven.
Research snapshot · updated Nov 12, 2026
Core thesis
Katalin Kariko (Nobel 2023) and Drew Weissman's nucleoside modification breakthrough enabled COVID vaccines. Moderna ($100B+ peak valuation) and BioNTech (Ugur Sahin) are now applying mRNA to cancer (personalised neoantigen vaccines), flu, RSV, CMV, and rare diseases. The platform advantage: once you can make one mRNA drug, you can make any — the manufacturing is identical. The challenge: moving beyond vaccines to therapeutic proteins and gene editing delivery.
State of the art (2026)
mRNA in 2026 is two stories pulling in opposite directions. On the science, oncology is delivering: Moderna and Merck reported sustained 5-year Phase 2b data for intismeran autogene (mRNA-4157) plus KEYTRUDA at ASCO in June 2026 (49% reduction in recurrence or death in resected melanoma), with the Phase 3 INTerpath-001 readout still expected this year; BioNTech-Genentech autogene cevumeran showed durable T-cell memory in pancreatic cancer at AACR 2026. On the politics, the US is retreating: HHS wound down roughly $500m of BARDA mRNA programmes in August 2025, and the FDA issued a refusal-to-file on Moderna mRNA-1010 before reversing to an August 2026 PDUFA date. The combination vaccine path (mRNA-1083) was withdrawn and is being resubmitted. Personalised oncology, not respiratory vaccines, now carries the platform thesis.
Explore the deeper analysis in CanaryIQ
Explore what is covered below. These previews show the structure; log in to read the full analysis.
Signal stack
Evidence stacked leading → lagging
10 signals
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
6 tracked
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what, and who depends on whom
43 players · 6 layers
Landscape map
Who builds what, and who depends on whom
Catalyst calendar
Dated events that will move the position
9 ahead
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
7 milestones
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers, each with a condition for removing it
19 · 20
Watchlists
Companies, people and papers, each with a condition for removing it
Decision frameworks
What our view means for your job
Locked
Decision frameworks
What our view means for your job
Thesis changelog
When our view changed, and why
9 updates
Thesis changelog
When our view changed, and why
Change our mind
3 disconfirming conditions
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and a record of every time our view on mRNA therapeutics has changed. All of it is in CanaryIQ.